Tong Yao, Zhao Ke-Ke, Feng Dong, Biswal Manas, Zhao Pei-Quan, Wang Zhao-Yang, Zhang Yun
Eye Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China; Department of Ophthalmology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.
Department of Ophthalmology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
Int J Ophthalmol. 2016 Jul 18;9(7):1028-37. doi: 10.18240/ijo.2016.07.16. eCollection 2016.
To compare the effect of anti-vascular endothelial growth factor (VEGF) monotherapy versus photodynamic therapy (PDT) and anti-VEGF combination treatment in age-related macular degeneration (AMD).
A computerized online search was performed using PubMed, Web of Science and the Cochrane Library. Studies that compared anti-VEGF monotherapy with PDT and anti-VEGF combination treatment of AMD and were designed as randomized controlled trials were included. The means and standard deviations of the best-corrected visual acuity (BCVA), central retinal thickness (CRT), number of treatments and proportions of patients who gained BCVA ≥15, 10, 5, or 0 letters at 12(th) month were extracted. A systematic review and Meta-analysis of the comparison of the two approaches was conducted using Review Manager 5.2. Subgroup. A sensitivity analysis was also performed.
Eight studies were included. When the subgroup and sensitivity analysis was conducted, the results indicated that in the findings that included the monotherapy group and PDT (standard fluence, SF) group of Kaiser's study, the patients in the monotherapy group had a better BCVA compared with the combination group at 12(th) month in the PDT (SF) subgroup [weighted mean difference (WMD): 3.54; 95%CI: 0.36 to 6.73; P=0.03], and there were more patients who gained ≥15 letters of BCVA in the monotherapy group compared with the combination group in the total result [odds ratio (OR): 1.41; 95%CI: 1.02 to 1.95; P=0.04]. The same conclusion was obtained in the total result that included the monotherapy group and PDT (reduced fluence, RF) group of Kaiser's study (OR: 1.56; 95%CI: 1.13 to 2.15; P=0.007). However, there were no significant differences in the other indexes between the two therapies.
We found that anti-VEGF monotherapy is more effective on the recovery of visual acuity than combination therapy and more researches with lager sample size should be performed to study on the effect of the two therapy approaches on CRT and number of injections.
比较抗血管内皮生长因子(VEGF)单药治疗与光动力疗法(PDT)及抗VEGF联合治疗在年龄相关性黄斑变性(AMD)中的效果。
使用PubMed、科学网和考克兰图书馆进行计算机在线检索。纳入比较抗VEGF单药治疗与PDT及抗VEGF联合治疗AMD且设计为随机对照试验的研究。提取最佳矫正视力(BCVA)、视网膜中央厚度(CRT)、治疗次数以及在第12个月时BCVA提高≥15、10、5或0字母的患者比例的均值和标准差。使用Review Manager 5.2对两种治疗方法的比较进行系统评价和Meta分析。亚组分析。还进行了敏感性分析。
纳入8项研究。进行亚组和敏感性分析时,结果表明,在包含凯泽研究中单一疗法组和PDT(标准光通量,SF)组的研究结果中,在PDT(SF)亚组中,单一疗法组患者在第12个月时的BCVA优于联合治疗组[加权均数差(WMD):3.54;95%可信区间(CI):0.36至6.73;P = 0.03],且在总结果中,单一疗法组中BCVA提高≥15字母的患者比联合治疗组更多[比值比(OR):1.41;95%CI:1.02至1.95;P = 0.04]。在包含凯泽研究中单一疗法组和PDT(降低光通量,RF)组的总结果中也得出相同结论(OR:1.56;95%CI:1.13至2.15;P = 0.007)。然而,两种治疗方法在其他指标上无显著差异。
我们发现抗VEGF单药治疗在视力恢复方面比联合治疗更有效,应进行更多大样本研究以探讨两种治疗方法对CRT和注射次数的影响。